ARTIDIS

The company develops a nanomechanical profiling platform that measures the physical and biomechanical properties of tumor tissue to predict cancer aggressiveness and metastatic potential. Its technology utilizes atomic force microscopy to analyze biopsy samples within hours, providing quantitative data on the tumor microenvironment to assist researchers and clinicians in treatment optimization. The platform is designed for use in clinical research, drug development, and point-of-care diagnostics.